Disproportionality analysis of cardiovascular adverse events reported to the FDA adverse event monitoring system with monoclonal antibodies targeting type 2 inflammation
Disproportionality analysis of cardiovascular adverse events reported to the FDA adverse event monitoring system with monoclonal antibodies targeting type 2 inflammation. // Heart & Lung. – URL: https://www.sciencedirect.com/science/article/pii/S0147956326002438?dgcid=rss_sd_all
Disproportionality analysis of cardiovascular adverse events reported to the FDA adverse event monitoring system with monoclonal antibodies targeting type 2 inflammation. Heart & Lung. https://www.sciencedirect.com/science/article/pii/S0147956326002438?dgcid=rss_sd_all
“Disproportionality analysis of cardiovascular adverse events reported to the FDA adverse event monitoring system with monoclonal antibodies targeting type 2 inflammation.” Heart & Lung.
@article{article116803,
title = {Disproportionality analysis of cardiovascular adverse events reported to the FDA adverse event monitoring system with monoclonal antibodies targeting type 2 inflammation},
journal = {Heart \& Lung},
url = {https://www.sciencedirect.com/science/article/pii/S0147956326002438?dgcid=rss_sd_all}
}